Intervention not reported
Salt intake in grams per day ‐ men only (n = 9 countries) · ‐level interventions in national government jurisdictions to reduce sodium consumption
1 finding from 1 review
Intervention not reported
Death from any cause prior to hospital discharge · Neonates with PPHN
The intervention showed no clear difference in death from any cause prior to hospital discharge (low certainty).
1 finding from 1 review
RR 0.2 [0.02, 1.77]
37 participants
Low
Intervention not reported
Percentage of infants that showed improvement in OI by at least 20% by the end of therapy · Neonates with PPHN
1 finding from 1 review
no estimate extracted
39 participants
Low
Intervention not reported
Adverse neurological outcomes at six months of age · Neonates with PPHN
1 finding from 1 review
no estimate extracted
37 participants
Low
Intervention not reported
Cerebral Palsy · Neonates with PPHN
1 finding from 1 review
no estimate extracted
37 participants
Low
Intervention not reported
Deafness · Neonates with PPHN
1 finding from 1 review
no estimate extracted
37 participants
Low
Intervention not reported
Need for ECMO prior to discharge · Neonates with PPHN
1 finding from 1 review
no estimate extracted
21 participants
Low
Intervention not reported
Total duration of mechanical ventilation (days) · Neonates with PPHN
The intervention showed no clear difference in total duration of mechanical ventilation (days) (low certainty).
1 finding from 1 review
no estimate extracted
37 participants
Low
Intervention not reported
Duration of iNO therapy (days) · Neonates with PPHN
1 finding from 1 review
no estimate extracted
21 participants
Low
Intervention not reported
Total duration of mechanical ventilation (days) · Neonates with PPHN
1 finding from 1 review
no estimate extracted
21 participants
Low
Prolonged abstinence at longest · smokers with COPD
Behavioural treatment probably leads to higher prolonged abstinence at longest compared with no treatment or usual care (moderate certainty).
1 finding from 1 review
Prolonged abstinence at longest · smokers with COPD
1 finding from 1 review
Point prevalence abstinence at longest · smokers with COPD
Pharmacological treatment probably leads to higher point prevalence abstinence at longest compared with a different pharmacological treatment (moderate certainty).
1 finding from 1 review
Prolonged abstinence at longest · smokers with COPD
1 finding from 1 review
Point prevalence abstinence at longest · smokers with COPD
1 finding from 1 review
Point prevalence abstinence at longest · smokers with COPD
1 finding from 1 review
Prolonged abstinence at longest · smokers with COPD
1 finding from 1 review
Point prevalence abstinence at longest · smokers with COPD
1 finding from 1 review
Prolonged abstinence at longest · smokers with COPD
Pharmacological treatment leads to higher prolonged abstinence at longest compared with placebo (high certainty).
5 findings from 1 review
RR 2.53 [1.83, 3.5]
4 studies · 1429 participants
High
RR 2.6 [1.29, 5.24]
1 study · 370 participants
High
RR 2.03 [1.26, 3.28]
2 studies · 503 participants
Moderate
Show 2 more findings
Intervention not reported
Improvement in measures of health behavior at 24 to 48 months of · s
1 finding from 1 review